Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses

Orsini, James A.; Ryan, William G.; Carithers, Douglas S.; Boston, Raymond C.

doi:10.2460/ajvr.73.5.664

Cited by 49 publications

(41 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As such, the dose of 0.5 mg/kg used in our study was based on pharmacokinetic information available in the horse labeled for use at 0.1 mg/kg. The equineapproved dose demonstrated analgesia in naturally occurring lameness following multiple daily doses (Orsini et al, 2012). More recently, it has been suggested to use a loading dose in horses to achieve steady state drug concentrations more quickly (Cox et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

The effects of firocoxib on cautery disbudding pain and stress responses in preweaned dairy calves

Stock

Millman

Barth

et al. 2015

Journal of Dairy Science

View full text Add to dashboard Cite

Perioperative analgesic effects of oral firocoxib following cautery disbudding were investigated in preweaned calves. Twenty Holstein calves approximately 4 to 6wk old received a single oral dose of firocoxib, a nonsteroidal antiinflammatory, at 0.5mg/kg (n=10) or placebo (n=10) in a randomized controlled clinical trial. Responses, including ocular temperature determined by infrared thermography, pressure algometry measuring mechanical nociception threshold, and heart rate, were evaluated at 2, 4, 7, 8, and 24h after cornual nerve block and cautery disbudding. Blood samples were collected over 96h and analyzed for plasma cortisol and substance P concentrations by RIA. Additionally, ex vivo prostaglandin E2 concentrations were determined over a 72-h study period using an enzyme immunoassay. Data were analyzed using a linear mixed effects model with repeated measures. An inhibition of ex vivo prostaglandin E2 synthesis was observed from 12 to 48h following disbudding in calves treated with firocoxib. Cautery disbudding was associated with an increased nociception for the duration of sampling (24h). During the initial 24-h period following disbudding, no difference in response between treatment groups was noted. Following 24h, mean cortisol concentrations diverged between the 2 study groups with placebo-treated calves having increased cortisol concentrations at approximately 48h after disbudding. Furthermore, the overall integrated cortisol response as calculated as area under the effect curve tended to be reduced in firocoxib-treated calves. The prolonged effects of cautery dehorning require further investigation. Moreover, the effect of firocoxib on cortisol reduction observed in this study requires additional exploration.

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of firocoxib on cautery disbudding pain and stress responses in preweaned dairy calves

Stock

Millman

Barth

et al. 2015

Journal of Dairy Science

View full text Add to dashboard Cite

show abstract

“…Firocoxib was administered at 0.1 mg/kg once daily, a common dose in equine practice and according to package label directions. This dosing regimen was chosen to mimic the most frequent clinical use of this drug in our practice setting and for its efficacy to treat pain associated with osteoarthritis . Some publications, however, have reported that firocoxib concentrations reach a steady‐state sooner after administration of a loading dose because it may take up to 7 days to achieve steady‐state concentration with a once daily 0.1‐mg/kg dose.…”

Section: Discussionmentioning

confidence: 99%

Effect of selective versus nonselective cyclooxygenase inhibitors on gastric ulceration scores and intestinal inflammation in horses

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The authors concluded that firocoxib was a safe treatment for musculoskeletal pain and lameness in horses with OA, with only four of 467 horses (0.9%) having adverse effects, which included edema of lips and gums, mild episodes of colic, and mild oral ulcers. 53 Without a control group in this study, there was likely a very high bias for veterinarians and owners to identify the horses as improved because they knew the horse was receiving a treatment, which is comparable to the control horses improving on clinical evaluations in the first study identified. This is an indication that more controlled studies with objective measures are needed to truly assess firocoxib's effect on lameness.…”

Section: Effect Of Firocoxib On Oamentioning

confidence: 94%

Use of firocoxib for the treatment of equine osteoarthritis

Donnell¹,

Frisbie²

2014

VMRR

View full text Add to dashboard Cite

This review presents the pathogenesis and medical treatment of equine osteoarthritis (OA), focusing on firocoxib. Inhibition of prostaglandin E 2 remains a fundamental treatment for decreasing clinical symptoms (ie, pain and lameness) associated with OA in horses. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the production of prostaglandin E 2 from the arachidonic acid pathway, continue to be a mainstay for the clinical treatment of OA. Firocoxib is a cyclooxygenase (COX)-2-preferential NSAID that has been shown to be safe and to have a 70% oral bioavailability in the horse. Three clinical reports identified symptom-modifying effects (reduction in pain and/or lameness) in horses with OA administered the once-daily recommended dose (0.1 mg/kg) of oral firocoxib following 7 days of administration. Other reports have suggested that a one-time loading dose (0.3 mg/kg) of firocoxib provides an earlier (1-3 days) onset of action compared to the recommended dose. It is noteworthy that OA disease-modifying effects have been reported in horses for other COX-2-preferential NSAIDs (meloxicam and carprofen), but have not been attributed to firocoxib due to a lack of investigation to date.

show abstract

Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses

Abstract: Firocoxib significantly improved lameness scores throughout the 14-day period with few adverse effects. Firocoxib can be a safe cyclooxygenase-2-specific NSAID for the treatment of musculoskeletal pain and lameness associated with osteoarthritis.

Cited by 49 publications

References 13 publications

The effects of firocoxib on cautery disbudding pain and stress responses in preweaned dairy calves

The effects of firocoxib on cautery disbudding pain and stress responses in preweaned dairy calves

Effect of selective versus nonselective cyclooxygenase inhibitors on gastric ulceration scores and intestinal inflammation in horses

Use of firocoxib for the treatment of equine osteoarthritis

Contact Info

Product

Resources

About